Precigen reports first quarter 2025 financial results and business updates

Prgn-2012 has the potential to be the first- and best-in-class treatment for rrp company's bla for prgn-2012 for the treatment of adults with rrp is under priority review by the fda with a pdufa target action date set for august 27, 2025 rrp is a rare, debilitating chronic disease with approximately 27,000 adult patients in the us and more than 125,000 patients outside of the us company continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch company and recurrent respiratory papillomatosis foundation to host the 2025 international rrp awareness day on june 11 cash, cash equivalents, and investments of $81.0 million as of march 31, 2025 are anticipated to fund operations into 2026, beyond the potential 2025 commercial launch of prgn-2012 germantown, md. , may 14, 2025 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2025 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking